Boston – September 24, 2021 – Cooley advised Lightstone Ventures, a global venture capital firm investing in biotech and medtech companies, on the closing of Lightstone Ventures III, an over-subscribed fund that exceeded its targeted raise with $375 million in capital commitments. Lawyers Nicole Peppe, Casey Schulte and Rachel Goddard led the Cooley team advising Lightstone Ventures.
The new fund will invest in early-stage companies developing high-impact therapeutics and technologies that have the potential to change patients’ lives.
“We are very excited for the future of Lightstone and the important work that this new fund will enable,” Mike Carusi, general partner at Lightstone, said in a news release. “Our investment philosophy is guided by a commitment not just to exciting ideas but to the people leading them forward. This is an important moment for the firm that builds upon the successes we have had with our previous two funds and the companies we have invested in that are already making an impact on patients. We look forward to continuing our partnership with driven entrepreneurs developing therapies and technologies that have the potential to be industry-leading products.”
Since its inception in 2012, Lightstone has invested in more than 30 companies, all of which share a commitment to translating scientific breakthroughs into clinically and commercially meaningful therapies and technologies.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,300 lawyers across 17 offices in the United States, Asia and Europe.